NovaBay Pharmaceuticals, Inc. - Common Stock, $0.01 par value (NBY)
CUSIP: 66987P409
Q3 2024 13F Holders as of 30 Sep 2024
- Type / Class
- Equity / Common Stock, $0.01 par value
- Shares outstanding
- 26,643,793
- Total 13F shares
- 125,970
- Share change
- +114,469
- Total reported value
- $87,462
- Price per share
- $0.69
- Number of holders
- 12
- Value change
- +$79,537
- Number of buys
- 8
Quarterly Holders Quick Answers
What is CUSIP 66987P409?
CUSIP 66987P409 identifies NBY - NovaBay Pharmaceuticals, Inc. - Common Stock, $0.01 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 66987P409:
Top shareholders of NBY - NovaBay Pharmaceuticals, Inc. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Andrew D. Jones |
3/4/5
|
CFO |
—
class O/S missing
|
127,461
|
$230,704 | — | 15 Feb 2023 | |
| Justin Hall |
3/4/5
|
CEO, GC and Director, Director |
—
class O/S missing
|
83,172
|
$150,541 | — | 14 Sep 2022 | |
| Julie Garlikov |
3/4/5
|
Director |
—
class O/S missing
|
30,000
|
$54,300 | — | 28 May 2024 | |
| Mijia Wu |
3/4/5
|
Director |
—
class O/S missing
|
30,000
|
$54,300 | — | 28 May 2024 | |
| Paul E. Freiman |
3/4/5
|
Director |
—
class O/S missing
|
30,000
|
$54,300 | — | 28 May 2024 | |
| Xinzhou Li |
3/4/5
|
Director, 10%+ Owner |
—
class O/S missing
|
30,000
|
$54,300 | — | 21 May 2021 | |
| Yenyou Zheng |
3/4/5
|
Director |
—
class O/S missing
|
30,000
|
$54,300 | — | 28 May 2024 | |
| Yongxiang Zheng |
3/4/5
|
Director |
—
class O/S missing
|
30,000
|
$54,300 | — | 28 May 2024 | |
| UBS Group AG |
13F
|
Company |
0.03%
|
8,158
|
$18,029 | — | 30 Jun 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
3,293
|
$7,278 | — | 30 Jun 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
42
|
$94 | — | 30 Jun 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
3
|
$7 | — | 30 Jun 2024 | |
| NVWM, LLC |
13F
|
Company |
0%
|
3
|
$7 | — | 30 Jun 2024 | |
| Blue Trust, Inc. |
13F
|
Company |
—
class O/S missing
|
37
|
$4 | — | 30 Jun 2024 | |
| Addison Advisors LLC |
13F
|
Company |
0%
|
1
|
$3 | — | 30 Jun 2024 | |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO |
13F
|
Company |
0%
|
1
|
$2 | — | 30 Jun 2024 |
Institutional Holders of NovaBay Pharmaceuticals, Inc. - Common Stock, $0.01 par value (NBY) as of Q3 2024
As of 30 Sep 2024,
NovaBay Pharmaceuticals, Inc. - Common Stock, $0.01 par value (NBY) was held by
12 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
125,970 shares.
The largest 10 holders included
C2C Wealth Management, LLC, GEODE CAPITAL MANAGEMENT, LLC, UBS Group AG, Virtu Financial LLC, Warberg Asset Management LLC, Tower Research Capital LLC (TRC), MORGAN STANLEY, BANK OF AMERICA CORP /DE/, NVWM, LLC, and Blue Trust, Inc..
This page lists
12
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
7
Q3 2024 holders
12
Holder diff
5
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 Value $ | Q3 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.